The invention relates to compounds of formula (I) wherein R
1
, R
1a
, R
1b
, R
2
, R
3
and X, X
1
, X
2
, X
3
have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.
The invention relates to compounds of formula (I)
wherein R
1
, R
1a
, R
1b
, R
2
, R
3
and X, X
1
, X
2
, X
3
have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.
[EN] NEW BRADYKININ B1 ANTAGONISTS<br/>[FR] NOUVEAUX ANTAGONISTES DU RÉCEPTEUR DE LA BRADYKININE B1
申请人:EVOTEC NEUROSCIENCES GMBH
公开号:WO2010020556A1
公开(公告)日:2010-02-25
The invention relates to compounds of formula (I) wherein R1, R1a, R1b, R2, R3 and X, X1, X2, X3 have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.